Drug Trial Radar · NCT06605222
A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
201
Planned (sponsor's estimate)
Start
Oct 4, 2024
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-7787 injection monotherapy for patients with advanced solid tumors. To explore the reasonable dosage of SHR-7787 injection monotherapy for patients with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
SHR-7787 injectionDrug
Firstly Dose Escalation and Dose Expansion of SHR-7787 injection monotherapy should be conducted.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated doseTime frame: first dose of study medication up to 21 days
- Recommended phase II doseTime frame: first dose of study medication up to 21 days
- Incidence and severity of adverse events (AEs)/serious adverse events (SAEs)Time frame: from signature completion of ICF to 60 days after the last dose or to the beginning of the new anti-cancer therapy, whichever came first, assessed up to 24 weeks
- Incidence of Dose Limited Toxicity (DLT)Time frame: from first dose to 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.